Menu
Back to User profile » Dr James Yao
Papers published by Dr James Yao:
Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma
Chamseddine S, LaPelusa M, Xiao L, Mohamed YI, Lee SS, Hu ZI, Hatia RI, Hassan M, Yao JC, Duda DG, Datar S, Amin HM, Kaseb AO
Journal of Hepatocellular Carcinoma 2024, 11:455-461
Published Date: 4 March 2024
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma
Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A
Journal of Hepatocellular Carcinoma 2021, 8:1129-1145
Published Date: 9 September 2021
Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study
Yao JC, Oh DY, Qian JM, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia LQ, Komoto I, Sriuranpong V, Shimada Y
OncoTargets and Therapy 2019, 12:1717-1728
Published Date: 28 February 2019
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4
Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R
OncoTargets and Therapy 2017, 10:5013-5030
Published Date: 16 October 2017
Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
Yao JC, Chan JA, Mita AC, Kundu MG, Hermosillo Reséndiz K, Hu K, Ravichandran S, Strosberg JR, Wolin EM
OncoTargets and Therapy 2017, 10:3177-3186
Published Date: 27 June 2017
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC
OncoTargets and Therapy 2016, 9:773-780
Published Date: 15 February 2016
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO
Journal of Hepatocellular Carcinoma 2016, 3:1-7
Published Date: 5 February 2016